Morgan Stanley
VRDN icon

Morgan Stanley’s Viridian Therapeutics VRDN Stock Holding History

Morgan Stanley’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17M Sell
870,162
-868,063
-50% -$25.8M ﹤0.01% 3108
2025
Q4 		$54.1M Buy
1,738,225
+1,546,284
+806% +$42.4M ﹤0.01% 2008
2025
Q3 		$4.14M Sell
191,941
-8,426
-4% -$152K ﹤0.01% 4296
2025
Q2 		$2.8M Sell
200,367
-141,428
-41% -$1.92M ﹤0.01% 4496
2025
Q1 		$4.61M Sell
341,795
-397,345
-54% -$6.77M ﹤0.01% 3990
2024
Q4 		$14.2M Sell
739,140
-270,739
-27% -$5.89M ﹤0.01% 3067
2024
Q3 		$23M Buy
1,009,879
+689,309
+215% +$11.3M ﹤0.01% 2664
2024
Q2 		$4.17M Sell
320,570
-241,971
-43% -$3.35M ﹤0.01% 4030
2024
Q1 		$9.85M Sell
562,541
-487,261
-46% -$9.45M ﹤0.01% 3357
2023
Q4 		$22.9M Buy
1,049,802
+716,079
+215% +$11.3M ﹤0.01% 3215
2023
Q3 		$5.12M Buy
333,723
+264,044
+379% +$5.04M ﹤0.01% 3719
2023
Q2 		$1.66M Sell
69,679
-363,455
-84% -$9.32M ﹤0.01% 4540
2023
Q1 		$11M Buy
433,134
+97,832
+29% +$3.14M ﹤0.01% 3053
2022
Q4 		$9.79M Buy
335,302
+170,544
+104% +$3.93M ﹤0.01% 3115
2022
Q3 		$3.38M Buy
164,758
+137,175
+497% +$2.47M ﹤0.01% 4005
2022
Q2 		$319K Sell
27,583
-7,346
-21% -$98.7K ﹤0.01% 5649
2022
Q1 		$646K Buy
34,929
+21,234
+155% +$408K ﹤0.01% 5251
2021
Q4 		$271K Buy
13,695
+3,773
+38% +$70.3K ﹤0.01% 5897
2021
Q3 		$163K Buy
9,922
+2,937
+42% +$43.1K ﹤0.01% 6103
2021
Q2 		$128K Buy
+6,985
New +$120K ﹤0.01% 6237
2021
Q1 		– Sell
-125
Closed -$2K – 7574
2020
Q4 		$2K Sell
125
-1
-0.8% -$15 ﹤0.01% 6905
2020
Q3 		$1K Hold
126
– – ﹤0.01% 6677
2020
Q2 		$2K Buy
126
+1
+0.8% +$11 ﹤0.01% 6466
2020
Q1 		$1K Buy
+125
New +$1.46K ﹤0.01% 6494
2019
Q4 		– Sell
-800
Closed -$9K – 6772
2019
Q3 		$9K Sell
800
-516
-39% -$11.4K ﹤0.01% 6248
2019
Q2 		$41K Sell
1,316
-2,244
-63% -$90.1K ﹤0.01% 5691
2019
Q1 		$149K Sell
3,560
-4,519
-56% -$204K ﹤0.01% 5211
2018
Q4 		$367K Buy
8,079
+4,712
+140% +$273K ﹤0.01% 4989
2018
Q3 		$282K Sell
3,367
-322
-9% -$30.4K ﹤0.01% 5300
2018
Q2 		$355K Sell
3,689
-1,916
-34% -$203K ﹤0.01% 5299
2018
Q1 		$589K Buy
5,605
+3,803
+211% +$413K ﹤0.01% 4906
2017
Q4 		$282K Buy
1,802
+617
+52% +$78.6K ﹤0.01% 5281
2017
Q3 		$163K Buy
1,185
+413
+53% +$69.5K ﹤0.01% 5433
2017
Q2 		$150K Buy
772
+418
+118% +$70.6K ﹤0.01% 5471
2017
Q1 		$66K Buy
+354
New +$61K ﹤0.01% 5749
2016
Q2 		– Hold
0
– – – 6664
2016
Q1 		– Hold
0
– – – 6725
2015
Q4 		– Hold
0
– – – 6803
2015
Q3 		– Hold
0
– – – 6732
2015
Q2 		– Hold
0
– – – 6757
2015
Q1 		– Hold
0
– – – 6663
2014
Q4 		– Hold
0
– – – 6677
2014
Q3 		– Hold
0
– – – 6667

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley's VRDN Position: Q1 2026 in Review

Morgan Stanley reduced its Viridian Therapeutics (VRDN) stake by 50% in Q1 2026, selling an estimated $25.8M and leaving 870,162 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #3108.

Morgan Stanley first reported a position in VRDN in Q1 2017 and has held it in 35 quarters since. The position peaked at $54.1M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Morgan Stanley held 870,162 shares of Viridian Therapeutics worth $17M as of Q1 2026.
  • Morgan Stanley sold 868,063 Viridian Therapeutics shares in Q1 2026, an estimated $25.8M.
  • Viridian Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3108 holding.
  • Morgan Stanley first reported a position in Viridian Therapeutics in Q1 2017 and has held it in 35 quarters since.
  • Morgan Stanley's Viridian Therapeutics position peaked at $54.1M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.